2.84
0.35%
+0.010
Opthea Limited ADR stock is currently priced at $2.84, with a 24-hour trading volume of 16,543.
It has seen a +0.35% increased in the last 24 hours and a -14.97% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.83 pivot point. If it approaches the $2.99 resistance level, significant changes may occur.
Previous Close:
$2.83
Open:
$2.7
24h Volume:
16,543
Market Cap:
$235.30M
Revenue:
$117.10K
Net Income/Loss:
$-161.61M
P/E Ratio:
-1.1695
EPS:
-2.4283
Net Cash Flow:
-
1W Performance:
-11.25%
1M Performance:
-14.97%
6M Performance:
+10.51%
1Y Performance:
-8.68%
Opthea Limited ADR Stock (OPT) Company Profile
Name
Opthea Limited ADR
Sector
Industry
Phone
61 3 9826 0399
Address
650 Chapel Street, Suite 0403 Level 4, South Yarra
Opthea Limited ADR Stock (OPT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-08-22 | Initiated | H.C. Wainwright | Buy |
Apr-26-22 | Initiated | SVB Leerink | Outperform |
Nov-17-20 | Initiated | Citigroup | Buy |
Nov-11-20 | Initiated | Oppenheimer | Outperform |
Nov-11-20 | Initiated | SVB Leerink | Outperform |
Nov-11-20 | Initiated | Truist | Buy |
View All
Opthea Limited ADR Stock (OPT) Latest News
Market Insight: Opthea Limited ADR (OPT)'s Notable Drop, Closing at 3.00 – DWinneX - The Dwinnex
The Dwinnex
Market Insight: Opthea Limited ADR (OPT)'s Notable Drop, Closing at 3.00 – DWinneX - The Dwinnex
The Dwinnex
2 Stocks Under $10 Wall Street Says Are 'Strong Buys' - Barchart
Barchart
Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD
GlobeNewswire Inc.
Opthea (NASDAQ:OPT) Shares Down 0.6% - Defense World
Defense World
2 Stocks Under $10 Wall Street Says Are 'Strong Buys' - Barchart
Barchart
Opthea Limited ADR Stock (OPT) Financials Data
Opthea Limited ADR (OPT) Revenue 2024
OPT reported a revenue (TTM) of $117.10 thousand for the quarter ending December 31, 2023, a +239.07% rise year-over-year.
Opthea Limited ADR (OPT) Net Income 2024
OPT net income (TTM) was -$161.61 million for the quarter ending December 31, 2023, a -181.90% decrease year-over-year.
Opthea Limited ADR (OPT) Earnings per Share 2024
OPT earnings per share (TTM) was -$2.4059 for the quarter ending December 31, 2023, a -101.79% decline year-over-year.
About Opthea Limited ADR
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Cap:
|
Volume (24h):